ABOUT US
- ABOUT US
-
CEO’s Greetings
CEO’s Greetings
is making a big-hearted
challenge to achieve
super-gap technological
innovation!
South Korea is the world’s second-largest country
based on the scale of biopharmaceutical manufacturing and
is a key global country in biopharmaceutical manufacturing with
several global companies, including the No.1 company
in the biopharmaceutical CMO/CDMO market.
In parallel, the Korean government designated
the bio-industry as the fourth national advanced strategic
industry in 2023 and is conducting large-scale investments
and R&D jointly with the private sector.
CEO CCRIPO Inc.
However, the South Korea imports most technologies, materials, equipment and facilities required for biopharmaceutical manufacturing, resulting in more than 45 percent of the total sales of domestic biopharmaceutical CMO/CDMO companies flowing overseas annually. The fundamental and main reasons for this imbalance and distorted structure in the biopharmaceutical manufacturing field are the low localization rate of raw and auxiliary materials at about 5 percent, the absence of core technologies related to biopharmaceutical manufacturing, and the conservative approach to new technologies.
CCRIPO Inc. is a startup business that aims to become a global leader and partner by presenting a new standard for the next-generation purification process. We achieve this through the development of innovative super-gap core technologies for the full-cycle purification process in downstream processes, which incur the most costs in biopharmaceutical manufacturing. Our efforts are based on the core technology of the innovative next-generation purification platform (MIDAS™ system). This platform will lead the new paradigm of protein-based biopharmaceutical purification processes, which are expected to grow to about 33 trillion won annually.
To this end, we intend to concentrate on solving the fundamental issues facing biopharmaceutical purification processes and to present a new direction for biopharmaceutical manufacturing by developing an innovative smart platform technology characterized by its extremely rapid, very low cost, high yield & purity, very ease and simplicity, scalability and extensibility, and eco-friendliness.
CCRIPO Inc. is pioneering on a path based on a different perspective and thought, aimed at creating new opportunities, values, and paradigms through the convergence of diversity and innovative creation, thereby leading the global popularization and generalization of biopharmaceutical. We kindly ask for your interest, support and participation in this journey of CCRIPO Inc., and invite you to join us. Thank you!
CEO CCRIPO Inc.Dae Heon Kim